TYK2 and psoriasis: To validate rs34536443 as a surrogate for therapeutic TYK2 inhibition, we confirmed that each copy of the minor allele, representing partial TYK2 inhibition, was associated with lower risk of psoriasis (OR 0.48, 95% CI 0.39‐0.58, P = 9.01 × 10−14) and other autoimmune diseases (Table 1).